Linked Life Data

16193258

Source:http://linkedlifedata.com/resource/pubmed/id/16193258

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2005-9-29
pubmed:abstractText
Recent studies indicate that minocycline exerts neuroprotective effects in vitro and in vivo, and suggest that the drug may represent a novel therapeutic approach to amyotrophic lateral sclerosis (ALS). In this study we investigated the safety of combined treatment with minocycline and riluzole in ALS. Twenty ALS patients were randomised into two groups and administered either riluzole (50 mg b.i.d.) or riluzole and minocycline (100 mg i.d.) for 6 months. Disease progression was measured by means of the ALS-Functional Rating Scale score at monthly intervals. Respiratory function was measured at the beginning of the study and repeated after 3 and 6 months of treatment. Combined treatment with minocycline and riluzole was not followed by significant side effects. This pilot study shows that minocycline and riluzole can be taken safely together. Further trials are needed to assess efficacy of such treatment.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
1590-1874
pubmed:author
pubmed:issnType
Print
pubmed:volume
26
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
285-7
pubmed:meshHeading
pubmed:year
2005
pubmed:articleTitle
Minocycline in amyotrophic lateral sclerosis: a pilot study.
pubmed:affiliation
Dipartimento di Scienze Neurologiche, II Facoltà di Medicina e Chirurgia, Università di Roma La Sapienza, Clinica Neurologica, Ospedale Sant Andrea, Via di Grottarossa 1035, I-00189 Rome, Italy. francesco.pontieri@ospedalesantandrea.it
pubmed:publicationType
Journal Article, Clinical Trial, Randomized Controlled Trial